Slovenian major Krka has enjoyed a solid start to 2024, welcoming 8% sales growth to €400.2m ($435m) for its prescription Pharmaceuticals segment in the first three months of the year and a group earnings before interest, tax, depreciation and amortization margin of 28.5%, “well above guidance.”
The Krka group’s largest region in terms of sales remained Eastern Europe, where overall revenues climbed by 9% to €156.4m...







